• LAST PRICE
    3.0000
  • TODAY'S CHANGE (%)
    Trending Down-0.0800 (-2.5974%)
  • Bid / Lots
    3.0000/ 19
  • Ask / Lots
    3.0100/ 43
  • Open / Previous Close
    3.1000 / 3.0800
  • Day Range
    Low 3.0000
    High 3.1750
  • 52 Week Range
    Low 0.9500
    High 4.1598
  • Volume
    373,694
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.08
TimeVolumeNUVB
09:32 ET142713.1
09:34 ET2003.13
09:36 ET190633.15
09:38 ET73983.15
09:39 ET40003.156
09:41 ET102993.165
09:43 ET30433.165
09:45 ET15193.17
09:48 ET45803.16
09:50 ET12333.165
09:52 ET49873.165
09:54 ET9003.168
09:56 ET62903.15
09:57 ET2193.149
10:01 ET76083.13
10:03 ET23893.12
10:06 ET40723.095
10:08 ET54093.1
10:10 ET9053.1
10:12 ET20983.1201
10:14 ET8413.125
10:15 ET2003.125
10:17 ET95573.1499
10:19 ET30003.145
10:21 ET74803.145
10:24 ET45403.12
10:26 ET37443.13
10:28 ET22593.13
10:30 ET6723.125
10:32 ET43403.1201
10:33 ET10073.11
10:35 ET12533.115
10:37 ET23783.1
10:39 ET2963.095
10:42 ET3003.09
10:44 ET14003.105
10:46 ET3003.105
10:48 ET2003.105
10:50 ET19363.115
10:51 ET1263.115
10:53 ET1003.115
10:55 ET3003.11
10:57 ET37593.11
11:00 ET6003.105
11:02 ET46483.09
11:04 ET2003.1
11:06 ET40583.1
11:08 ET1003.1
11:09 ET8503.1
11:11 ET4003.105
11:13 ET50213.115
11:15 ET47443.1
11:20 ET1003.105
11:22 ET3003.11
11:24 ET1003.105
11:26 ET2003.11
11:33 ET69613.115
11:36 ET1683.115
11:38 ET1003.12
11:40 ET2613.12
11:42 ET42313.125
11:44 ET6723.1201
11:45 ET3003.13
11:47 ET7793.125
11:49 ET1003.13
11:51 ET2003.13
11:54 ET8003.125
11:58 ET7003.13
12:00 ET2003.13
12:02 ET96923.12
12:03 ET14003.125
12:05 ET1003.125
12:07 ET90933.105
12:09 ET3783.105
12:12 ET5003.1
12:14 ET147513.08
12:16 ET7643.085
12:18 ET4003.08
12:20 ET32053.0762
12:21 ET9943.07
12:23 ET3003.07
12:25 ET68723.07
12:27 ET7003.07
12:30 ET13753.06
12:34 ET22033.05
12:38 ET2003.06
12:39 ET5003.055
12:41 ET3003.05
12:43 ET3003.055
12:45 ET14003.05
12:48 ET1003.05
12:50 ET8513.05
12:52 ET1003.055
12:54 ET11143.06
12:56 ET13113.05
12:57 ET42033.045
12:59 ET10603.04
01:01 ET34393.035
01:03 ET14123.03
01:06 ET39733.03
01:08 ET5003.03
01:10 ET34373.03
01:12 ET109243.04
01:14 ET6003.03
01:15 ET6003.03
01:17 ET56923.03
01:19 ET4003.03
01:21 ET5403.03
01:24 ET4333.03
01:26 ET40143.02
01:28 ET39543.02
01:30 ET16243.02
01:32 ET102993.025
01:33 ET13003.02
01:35 ET7003.02
01:37 ET10003.025
01:39 ET21003.03
01:42 ET10003.025
01:44 ET190993
01:46 ET3003
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNUVB
Nuvation Bio Inc
761.3M
-9.5x
---
United StatesVRDN
Viridian Therapeutics Inc
772.9M
-2.7x
---
United StatesPROK
ProKidney Corp
780.8M
-6.4x
---
United StatesPRAX
Praxis Precision Medicines Inc
754.1M
-2.8x
---
United StatesCOGT
Cogent Biosciences Inc
785.9M
-3.3x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
730.9M
-8.1x
---
As of 2024-05-28

Company Information

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Contact Information

Headquarters
357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103
Phone
415-754-3517
Fax
302-636-5454

Executives

Independent Chair of the Board
Daniel Welch
President, Chief Executive Officer, Founder, Director
David Hung
Principal Accounting Officer, Principal Financial Officer
Moses Makunje
Chief People Officer
Stacy Markel
Chief Scientific Officer
Gary Hattersley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$761.3M
Revenue (TTM)
$0.00
Shares Outstanding
247.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.41
EPS
$-0.31
Book Value
$2.76
P/E Ratio
-9.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.